Genedrive PLC Genedrive® Hepatitis C test in Asia Pacific
03 Aprile 2018 - 8:01AM
RNS Non-Regulatory
TIDMGDR
Genedrive PLC
03 April 2018
RNS Reach for release: 3 April 2018
genedrive plc ("genedrive" or the "Company")
genedrive to premier its Genedrive(R) Hepatitis C test in Asia
Pacific
Genedrive(R) HCV ID Kit to be presented at MEDLAB Asia Pacific
Exhibition & Congress
genedrive plc (AIM: GDR), the near patient molecular diagnostics
company, today announces it will premiere its Genedrive(R) HCV ID
Kit in the Asia Pacific region at the MEDLAB Asia Pacific
Exhibition & Congress in Singapore on 2-4 April 2018.
Genedrive(R) HCV ID Kit is a qualitative HCV assay, providing
results within 90 minutes and is designed for use in a
decentralised testing environment. It is performed on the company's
portable molecular diagnostics platform, Genedrive(R), and was
created to support the roll-out of direct-acting antivirals in low
and middle income countries.
genedrive recently announced first commercial sales of
instruments and assays to Sysmex Europe GmbH to cover Europe,
Middle East and Africa and Sysmex Asia Pacific Pte Ltd for the Asia
Pacific region, excluding India. In addition, the Genedrive(R) HCV
ID Kit's first external validation study was successfully conducted
in South Africa with results announced in early January 2018
showing 100% specificity and sensitivity in independent use,
confirming that our good clinical validation performance can be
translated into real-world settings.
MEDLAB is a significant and highly attended event in the Asia
Pacific region for leading companies to showcase their technologies
and innovations in the field of laboratory diagnostics. With over
4,000 delegates from around the world, the congress features
products in many areas including point of need and infectious
diseases.
The Genedrive(R) HCV-ID Kit will be presented and demonstrated
together with Sysmex Asia Pacific at booth M19 at the Suntec
Singapore Convention & Exhibition Centre.
- Ends -
For further details please contact:
genedrive plc
David Budd: CEO +44 (0)161 989 0245
Matthew Fowler: CFO
Peel Hunt LLP
James Steel
+44 (0)207 418 8900
Oliver Jackson
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Genedrive(R) HCV ID Kit has received CE-IVD
Certification and has been launched in Africa and Asia Pacific.
genedrive has distribution agreements with subsidiaries of Sysmex
Corporation for the distribution of the Genedrive(R) platform in
the EMEA and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd
for the distribution of the Genedrive(R) HCV ID Kit and
Genedrive(R) platform in India.
Further details can be found at: www.genedriveplc.com and
www.genedrive.com
About Hepatitis C
Hepatitis C (HCV) is an international public health challenge,
comparable to other major communicable diseases, including HIV,
tuberculosis and malaria. It is estimated that 150-200 million
people, or approximately 3% of the world's population, are living
with chronic HCV, and more than 350,000 people die yearly from HCV
related diseases. In 2016, WHO published the first global health
sector strategy on Hepatitis with a goal of eliminating viral
hepatitis as a major public health threat by 2030. New oral,
well-tolerated treatment regimens can achieve cure rates of over
90% however access to rapid, inexpensive and accurate diagnostics
are a critical bottleneck that must be addressed to eradicate
HCV.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABCGDSGDGBGID
(END) Dow Jones Newswires
April 03, 2018 02:01 ET (06:01 GMT)
Grafico Azioni Epistem (LSE:EHP)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Epistem (LSE:EHP)
Storico
Da Giu 2023 a Giu 2024